The DiviTum® TKa Test

The DuA Score - What It Means

DuA - DiviTum units of Activity

The score indicates a level of cell proliferation, which has been linked to the risk of cancer progression in a long list of studies1-10. Lower DiviTum® TKa levels are associated with lower likelihood of disease progression2,3,5.

The DiviTum TKa Test allows for an early warning about cancer progression in your patients.

References:

  1. Data from the DiviTum® TKa FDA 510 (k) Clearance: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K202852.pdf
  2. Paoletti C, Barlow WE, Cobain EF, et al. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clin Cancer Res. 2021; 27(22):6115-6123.
  3. Bergqvist M, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with
    a low risk of early progression (SWOG S0226). Biomarkers. 2023; 29:1-10.
  4. Malorni L, Tyekucheva S, Hilbers FS, et al. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer
    treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.
  5. Malorni L, Bianchini G, Caputo R, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus
    letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11.
  6. Krishnamurthy J, Luo J, Suresh R, et al. A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. NPJ Breast Cancer.
    2022;8(1):35.
  7. Albanell J, Williams A, Martínez MT, et al. “Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial”
    ASCO Annual Meeting 2024, J Clin Oncol 42, 2024 (suppl 16; abstr 1028)
  8. Howell S, Bergqvist M, Williams A, et al. “Thymidine kinase activity as a prognostic biomarker for first line CDK4/6 inhibitor efficacy in the Personalised Disease
    Monitoring in Metastatic Breast Cancer (PDM-MBC) study” San Antonio Breast Cancer Symposium 2024, Poster P5-02-16.
  9. Williams A, Bear H, Denkert C, et al. “Evaluation of proliferation biomarker serum thymidine kinase activity
    and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trial” San Antonio Breast Cancer Symposium 2024, Poster P1-09-06.
  10. Witkiewicz A, Schultz S, Knudsen ES et al.
    “Interrogating serum thymidine kinase activity with CDK4/6 inhibitor based therapies: real-world experience in the metastatic and adjuvant setting” San Antonio Breast Cancer Symposium 2024, Poster P2-05-16.

PLEASE SELECT ONE

Please specify your home location

USA
Europe/Rest of World